DE69813553D1 - Anwendung von akustooptischen und sonolumineszenten kontrastmitteln in diagnostischen verfahren - Google Patents

Anwendung von akustooptischen und sonolumineszenten kontrastmitteln in diagnostischen verfahren

Info

Publication number
DE69813553D1
DE69813553D1 DE69813553T DE69813553T DE69813553D1 DE 69813553 D1 DE69813553 D1 DE 69813553D1 DE 69813553 T DE69813553 T DE 69813553T DE 69813553 T DE69813553 T DE 69813553T DE 69813553 D1 DE69813553 D1 DE 69813553D1
Authority
DE
Germany
Prior art keywords
acustooptic
sonoluminescent
application
contrast agents
diagnostic procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69813553T
Other languages
English (en)
Other versions
DE69813553T2 (de
Inventor
Mark Henrichs
Raphael Wolfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Amersham Health AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health AS filed Critical Amersham Health AS
Application granted granted Critical
Publication of DE69813553D1 publication Critical patent/DE69813553D1/de
Publication of DE69813553T2 publication Critical patent/DE69813553T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0078—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion microemulsion, nanoemulsion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Semiconductor Lasers (AREA)
DE69813553T 1997-06-16 1998-05-19 Anwendung von akustooptischen und sonolumineszenten kontrastmitteln in diagnostischen verfahren Expired - Lifetime DE69813553T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712525.6A GB9712525D0 (en) 1997-06-16 1997-06-16 Method
GB9712525 1997-06-16
PCT/GB1998/001438 WO1998057666A1 (en) 1997-06-16 1998-05-19 Use of acousto-optical and sonoluminescence contrast agents

Publications (2)

Publication Number Publication Date
DE69813553D1 true DE69813553D1 (de) 2003-05-22
DE69813553T2 DE69813553T2 (de) 2004-03-04

Family

ID=10814250

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813553T Expired - Lifetime DE69813553T2 (de) 1997-06-16 1998-05-19 Anwendung von akustooptischen und sonolumineszenten kontrastmitteln in diagnostischen verfahren

Country Status (10)

Country Link
US (1) US6424857B1 (de)
EP (1) EP0991429B1 (de)
JP (1) JP2002504924A (de)
AT (1) ATE237363T1 (de)
AU (1) AU7443398A (de)
DE (1) DE69813553T2 (de)
ES (1) ES2196558T3 (de)
GB (1) GB9712525D0 (de)
PT (1) PT991429E (de)
WO (1) WO1998057666A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9710049D0 (en) * 1997-05-19 1997-07-09 Nycomed Imaging As Method
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US20090216118A1 (en) 2007-07-26 2009-08-27 Senorx, Inc. Polysaccharide markers
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
CA2775170C (en) 2000-11-20 2017-09-05 Senorx, Inc. An intracorporeal marker delivery system for marking a tissue site
US6984373B2 (en) 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
US20030200932A1 (en) 2001-02-16 2003-10-30 Toelken L. Taizo Ultrasound quality inspection of avian eggs
US6512839B1 (en) * 2001-02-21 2003-01-28 Ultra-Hatch, Inc. Ultrasound sex determination of avian hatchlings
US6757554B2 (en) 2001-05-22 2004-06-29 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Measurement of cardiac output and blood volume by non-invasive detection of indicator dilution
US7474906B2 (en) * 2001-05-22 2009-01-06 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Method for dye injection for the transcutaneous measurement of cardiac output
US8082016B2 (en) 2001-05-22 2011-12-20 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Measurement of cardiac output and blood volume by non-invasive detection of indicator dilution
US20080027298A1 (en) * 2001-05-22 2008-01-31 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern Californ System for Repetitive Measurements of Cardiac Output in Freely Moving Individuals
US8337444B2 (en) * 2001-05-22 2012-12-25 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Measurement of cardiac output and blood volume by non-invasive detection of indicator dilution for hemodialysis
US7354401B1 (en) 2002-06-19 2008-04-08 Toelken L Taizo Ultrasound sex determination for sorting of avian hatchlings
EP1587944A4 (de) 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
WO2003074005A2 (en) 2002-03-01 2003-09-12 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20030178616A1 (en) * 2002-03-25 2003-09-25 Prevenslik Thomas V. Cavity QED devices
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
EP1583473A2 (de) * 2003-01-16 2005-10-12 St. Johns University New York Stabilisierung von ir-fluoreszenten farbstoffen auf nanopartikel-basis
US7378081B2 (en) 2003-01-29 2008-05-27 Vincon Research Enterprises, Llc Composition and method for direct visualization of the human appendix
EP2284180B1 (de) 2003-03-03 2015-09-09 Dyax Corp. Verwendungen von Spezifisch an HGF-Rezeptor (cMET) bindenden Peptiden
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US20050107694A1 (en) * 2003-11-17 2005-05-19 Jansen Floribertus H. Method and system for ultrasonic tagging of fluorescence
JP4578817B2 (ja) * 2004-02-06 2010-11-10 オリンパス株式会社 外科手術用病変部同定システム
CN101019028B (zh) * 2004-09-10 2013-05-01 皇家飞利浦电子股份有限公司 用于组合的光学-超声成像的化合物和方法
US20210299056A9 (en) 2004-10-25 2021-09-30 Varian Medical Systems, Inc. Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
US9173573B2 (en) 2005-02-23 2015-11-03 Koninklijke Philips N.V. Imaging an object of interest
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
US8052658B2 (en) 2005-10-07 2011-11-08 Bard Peripheral Vascular, Inc. Drug-eluting tissue marker
US20090155182A1 (en) * 2005-12-09 2009-06-18 Invitrogen Corporation Optical in vivo imaging contrast agents and methods of use
FR2900043B1 (fr) * 2006-04-24 2008-07-04 Commissariat Energie Atomique Procede d'imagerie optique par fluorescence de tissus biologiques, notamment pour delimiter des regions d'interet des tissus a analyser par tomographie
US20070297988A1 (en) * 2006-06-21 2007-12-27 Bin Wu Optical probes for in vivo imaging
US20080294039A1 (en) * 2006-08-04 2008-11-27 Senorx, Inc. Assembly with hemostatic and radiographically detectable pellets
EP2079385B1 (de) 2006-10-23 2013-11-20 C.R.Bard, Inc. Brustkennzeichner
WO2008073965A2 (en) 2006-12-12 2008-06-19 C.R. Bard Inc. Multiple imaging mode tissue marker
WO2008076973A2 (en) 2006-12-18 2008-06-26 C.R.Bard Inc. Biopsy marker with in situ-generated imaging properties
JP2010534266A (ja) * 2007-07-25 2010-11-04 セロノバ バイオサイエンシーズ， インコーポレイテッド 治療および／または診断用途のための、色分けされ、大きさによって分けられた充填可能なポリマー粒子、ならびにそれらを調製し、そして使用する方法
EP2036577A1 (de) 2007-09-14 2009-03-18 mivenion GmbH Diagnostische Stoffe für die optische bildgebende Untersuchung auf der Basis von nanopartikulären Formulierungen
EP2476703A1 (de) 2011-01-14 2012-07-18 Bracco Imaging S.p.A Mit einem Bakterium kreuzreagierende menschliche Antikörper und ein Autoantigen aus atherosklerotischen Plaques
US20100268090A1 (en) * 2007-11-06 2010-10-21 Rubinstein Eduardo H Measurement of hematocrit and cardiac output from optical transmission and reflection changes
US8311610B2 (en) 2008-01-31 2012-11-13 C. R. Bard, Inc. Biopsy tissue marker
EP2147684A1 (de) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Selektiv gegen Metallproteasen wirkende Diagnosemittel
FR2934954B1 (fr) 2008-08-14 2011-07-22 Commissariat Energie Atomique Emulsion fluorescente de vert d'indocyanine
FR2934953B1 (fr) 2008-08-14 2011-01-21 Commissariat Energie Atomique Nanoemulsions de nanocristaux
FR2934955B1 (fr) 2008-08-14 2011-07-08 Commissariat Energie Atomique Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US8670818B2 (en) 2008-12-30 2014-03-11 C. R. Bard, Inc. Marker delivery device for tissue marker placement
WO2012095516A1 (en) 2011-01-14 2012-07-19 Bracco Imaging Spa Human antibodies cross-reacting with a bacterial and a self antigen from atherosclerotic plaques
US9138492B2 (en) 2012-02-23 2015-09-22 Canon Kabushiki Kaisha Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle
US8917442B2 (en) 2012-09-20 2014-12-23 Elwha Llc Focusing electromagnetic radiation within a turbid medium using ultrasonic modulation
US9232896B2 (en) 2012-09-20 2016-01-12 Elwha Llc Focusing electromagnetic radiation within a turbid medium using ultrasonic modulation
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
IT202100005123A1 (it) 2021-03-04 2022-09-04 Torino Politecnico Metodo ed apparato per immagine di contrasto in sonoluminescenza assistita da nanoparticelle in ambito medico diagnostico, in particolare oncologico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948975A (en) * 1988-09-08 1990-08-14 The United States Of America As Represented By The Secretary Of The Air Force Quantitative luminescence imaging system
CA2087412A1 (en) * 1992-01-17 1993-07-18 Joseph R. Lakowicz Ph and pco2 sensing by luminescent lifetimes and energy transfer
US5491344A (en) * 1993-12-01 1996-02-13 Tufts University Method and system for examining the composition of a fluid or solid sample using fluorescence and/or absorption spectroscopy
US5659173A (en) * 1994-02-23 1997-08-19 The Regents Of The University Of California Converting acoustic energy into useful other energy forms
GB9502065D0 (en) * 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media

Also Published As

Publication number Publication date
EP0991429B1 (de) 2003-04-16
WO1998057666A1 (en) 1998-12-23
WO1998057666A8 (en) 2000-01-20
US6424857B1 (en) 2002-07-23
ATE237363T1 (de) 2003-05-15
ES2196558T3 (es) 2003-12-16
AU7443398A (en) 1999-01-04
DE69813553T2 (de) 2004-03-04
GB9712525D0 (en) 1997-08-20
EP0991429A1 (de) 2000-04-12
JP2002504924A (ja) 2002-02-12
PT991429E (pt) 2003-09-30

Similar Documents

Publication Publication Date Title
DE69813553D1 (de) Anwendung von akustooptischen und sonolumineszenten kontrastmitteln in diagnostischen verfahren
DE69817360D1 (de) Verfahren zur photoakustische bilderzeugung
BR9813704A (pt) Utilização de um transdutor ultra-sonoro, e, aparelho de exploração ecográfica
NZ334191A (en) Method for improved selectivity in photo-activation and detection of molecular diagnostic agents
FI951379A (fi) Biohajoavista kopolymeereistä koostuvia mikrohiukkasvalmisteita
DE69839017D1 (de) Vorrichtung für medizinische handlungen durch fokusierten ultraschall hoher intensität
DE69029257T2 (de) Anordnung zur bestrahlung von laserstrahlen
ATE429171T1 (de) Verfahren und gerät zur bestimmung der autofluoreszenz von hautgewebe
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
DE69920425D1 (de) Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter
ATE204721T1 (de) Verfahren und therapiegerät zur erzeugung von ultraschall mit reduzierter kavitationsbildung
ATE210127T1 (de) 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung
DE59911408D1 (de) Instrument zum applizieren von licht, insbesondere laserlicht, im menschlichen oder tierischen körper
NO944805D0 (no) Mikropartikkel, fremgangsmåte for fremstilling samt anvendelse derav i diagnostikken
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
DE68922607D1 (de) Heizungsvorrichtung unter verwendung eines laserstrahls.
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
MX9101448A (es) Agentes quimioterapeuticos y metodo para hacerlos
SE9103837D0 (sv) Fluorescensdiagnostik av cancer utnyttjande delta-aminolevulinsyra
ATE452906T1 (de) Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE29520218U1 (de) Vorrichtung zur Erzeugung von aktiviertem Sauerstoff durch Bestrahlung mit UV-C-Strahlen sowie zur anschließenden Laserbestrahlung des mit diesem aktivierten Sauerstoff vermischtem Blutes vor Rückführung in den Körper
RU95107754A (ru) Способ лечения туберкулеза предстательной железы
IT1275604B1 (it) Dispositivo per la riduzione di stenosi di organi del corpo umano
NL8902780A (nl) Gouden naaldconstructie.

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GE HEALTHCARE AS, OSLO, NO

8328 Change in the person/name/address of the agent

Representative=s name: HAMMONDS LLP, LONDON, GB

R082 Change of representative

Ref document number: 991429

Country of ref document: EP

Representative=s name: J D REYNOLDS & CO., GB